IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-09

Study Completion Date

2026-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project will examine the impact of the nicotine dose and delivery rate on nicotine's abuse potential, versus its potentially beneficial effects on smoking urges and withdrawal. Will use pulsed IV nicotine administration which closely matches nicotine delivery by inhaled tobacco use.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Smoking by IV Pulsed Nicotine

NCT04488744

Smoking Cessation

COMPLETED EARLY_PHASE1

Nicotine Differences in Smokers

NCT05159934

Nicotine Dependence

COMPLETED PHASE1

The Effect of Nicotine Delivery Rate on Reinforcement

NCT03134339

Nicotine

COMPLETED EARLY_PHASE1

Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol

NCT03580525

Nicotine Dependence

COMPLETED EARLY_PHASE1

Addictive Threshold of Nicotine

NCT06096714

Smoking Addiction

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Seventy smokers will be randomized to nicotine doses of either 0.2 or 1 mg per 70 kg body weight. Across 5 test sessions, within each dose group, participants will be randomly assigned to a sequence of 5 treatment conditions: placebo (saline) and 4 different delivery rates of nicotine. In each session, participants will receive either nicotine- or saline-pulsed infusions that will be delivered every 30 seconds for a total of 10 pulsed infusions. While receiving the pulsed infusions, participants will inhale a tobacco-flavored EC without nicotine, which will allow for a closer matching of the sensory aspects of inhaled tobacco use. There are four pulse duration conditions for the nicotine sessions: 2-, 4-, 6- and 8-second pulses. For those assigned to 1.0 mg/70kg nicotine dose, the pulse duration conditions correspond to nicotine delivery rates of 50, 25, 16.6, and 12.5 mcg nicotine/second. For those assigned to 0.2 mg/70 kg dose, the corresponding delivery rates will be 10, 5, 3.3 and 2.5 mcg nicotine/second. Participants in both nicotine dose groups will each have one placebo test session wherein they will receive 10 pulsed-saline infusions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nicotine Dependence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

This will be a double-blind, placebo-controlled study employing a mixed design: nicotine dose as the between-subject and delivery rate as the within-subject factors.

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

delivery rate for nicotine dose 1mg/70kg

delivery rate 50,35, 16.6 and 12.5 ug per second

Group Type ACTIVE_COMPARATOR

low dose Nicotine

Intervention Type DRUG

IV nicotine infused over different delivery rates

Delivery rate for nicotine dose 0.2mg/70kg

delivery rate 10,5, 3.3 and 2.5

Group Type ACTIVE_COMPARATOR

high dose Nicotine

Intervention Type DRUG

IV Nicotine infused over different delivery rates

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

low dose Nicotine

IV nicotine infused over different delivery rates

Intervention Type DRUG

high dose Nicotine

IV Nicotine infused over different delivery rates

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

IV nicotine 1mg/70kg IV Nicotine 0.2/70kg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female and male, aged 21 to 55 years;
* past year daily cigarette use, verified by urine cotinine levels above 100 ng/ml -lifetime history of e-cigarette use; in good health as verified by medical history -screening examination, and screening laboratory tests
* women, -using acceptable birth control methods.

Exclusion Criteria

* History of major medical or psychiatric disorders that the physician investigator deems as contraindicated for the participant to be in the study
* risk factors for EVALI (E-cigarette or Vaping Product Use-Associated Lung Injury) including history of lung diseases (e.g., asthma or COPD), vaping THC or CBD
* regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics)
* current alcohol or substance use disorder for any other recreational or prescription drugs other than nicotine
* for women, pregnant as determined by pregnancy screening, or breast feeding
* seeking (or undergoing) treatment for tobacco dependence or smoking; reported aversion to e-cigarettes, or tobacco flavored e-liquid.

Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No